Ozempic is simply the brand name for the semaglutide medication formulated specifically for treating type 2 diabetes
P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and at least one weight-related comorbidity, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
All opinions and articles linked to and from this page are those of the individuals concerned and do not necessarily represent those of GOLO, LLC or its employees
Cristina Romano, Paolo Desenzani, Paola Pantanetti, Silvio Settembrini, Sebastiano Bruno Solerte declare no competing interests
adults would benefit from treatment with semaglutide